The AMLo Executive Team

Dr. Marie Labus
CHIEF EXECUTIVE OFFICER

Dr Marie Labus has over 16 years business experience including managing a spin-out company. In that time she has also undertaken leading roles in research strategy development, change management and various business development activities. Marie has significant experience in facilitating, developing and supporting a large and diverse portfolio of enterprise-related activities including protecting intellectual assets, project management, knowledge transfer, consultancy, CPD, patents, licensing, commercial services and Research and Development activities with the aim of commercialisation of research findings for patient benefit.

Dr. Marie Labus
CHIEF EXECUTIVE OFFICER

Dr Marie Labus has over 16 years business experience including managing a spin-out company. In that time she has also undertaken leading roles in research strategy development, change management and various business development activities. Marie has significant experience in facilitating, developing and supporting a large and diverse portfolio of enterprise-related activities including protecting intellectual assets, project management, knowledge transfer, consultancy, CPD, patents, licensing, commercial services and Research and Development activities with the aim of commercialisation of research findings for patient benefit.

Professor Penny Lovat
CHIEF SCIENTIFIC OFFICER

Professor Penny Lovat has over 30 years experience in translational medical research and is internationally renowned for her work in the melanoma field in which she has contributed to the characterization of the molecular events leading to deregulated cellular signalling in both cutaneous and uveal melanoma, with particular emphasis on apoptosis and autophagy and the development of novel biomarkers, therapeutic targets and therapeutic approaches to both prevent and treat metastatic disease. Penny has published over 70 manuscripts (current h index: 30) with >8,000 citations, including several publications in leading dermatology and cancer journals as well as being the principal investigator of numerous research studies funded both nationally and internationally. Penny has also served as a committee member of The British Society of Investigative Dermatology, and as a member of several grant advisory boards including for The British Skin Foundation.

Professor Penny Lovat
CHIEF SCIENTIFIC OFFICER

Professor Penny Lovat has over 30 years experience in translational medical research and is internationally renowned for her work in the melanoma field in which she has contributed to the characterization of the molecular events leading to deregulated cellular signalling in both cutaneous and uveal melanoma, with particular emphasis on apoptosis and autophagy and the development of novel biomarkers, therapeutic targets and therapeutic approaches to both prevent and treat metastatic disease. Penny has published over 70 manuscripts (current h index: 30) with >8,000 citations, including several publications in leading dermatology and cancer journals as well as being the principal investigator of numerous research studies funded both nationally and internationally. Penny has also served as a committee member of The British Society of Investigative Dermatology, and as a member of several grant advisory boards including for The British Skin Foundation.

Jane Meaney
MARKETING DIRECTOR

Jane Meaney has over 30 years of commercial experience gained in blue chip and start-up pharmaceutical and medical technology companies. She has very wide-ranging marketing experience in healthcare across the NHS and private sectors in UK and Europe. Most recently Jane worked as Marketing Director for an Oxford University spin-out company. She brought a CE-marked cancer biomarker to market and developed a novel digital pathology cancer prognostic device with the team; transforming the company from an academic spin-out to a fully functioning commercial entity. This experience will help AMLo become a successful commercial business. Jane is a biology graduate and an MBA.

Jane Meaney
MARKETING DIRECTOR

Jane Meaney has over 30 years of commercial experience gained in blue chip and start-up pharmaceutical and medical technology companies. She has very wide-ranging marketing experience in healthcare across the NHS and private sectors in UK and Europe. Most recently Jane worked as Marketing Director for an Oxford University spin-out company. She brought a CE-marked cancer biomarker to market and developed a novel digital pathology cancer prognostic device with the team; transforming the company from an academic spin-out to a fully functioning commercial entity. This experience will help AMLo become a successful commercial business. Jane is a biology graduate and an MBA.

 

Professor Philip Sloan
CHIEF HISTOPATHOLOGIST

Professor Sloan is a practicing pathologist specialising in head & neck, skin and bone & soft tissue pathology. Philip currently engages in research into advanced cellular therapies and novel diagnostic tests. He was director of the CEPA Biobank and co-director of the EPSRC/MRC Molecular Pathology Node, that merged in 2021 to form NovoPath. He has a particular interest and expertise in Quality Assurance for laboratory medicine and clinical trials.

Philip graduated from Newcastle University in 1974, gained his PhD from the University of Bristol in 1978. He was Professor of Experimental Pathology at the University of Manchester and R&D Director of CMHT until 2007. He has authored or co-authored over 300 peer reviewed publications and five books. Currently he a member of the WHO collaborating group for OMPDs and cancer, and is a lead author for ICCR guidelines. Philip is particularly enthusiastic about working with industry partners as well as academic researchers, for patient benefit.

Professor Philip Sloan
CHIEF HISTOPATHOLOGIST

Professor Sloan is a practicing pathologist specialising in head & neck, skin and bone & soft tissue pathology. Philip currently engages in research into advanced cellular therapies and novel diagnostic tests. He was director of the CEPA Biobank and co-director of the EPSRC/MRC Molecular Pathology Node, that merged in 2021 to form NovoPath. He has a particular interest and expertise in Quality Assurance for laboratory medicine and clinical trials.

Philip graduated from Newcastle University in 1974, gained his PhD from the University of Bristol in 1978. He was Professor of Experimental Pathology at the University of Manchester and R&D Director of CMHT until 2007. He has authored or co-authored over 300 peer reviewed publications and five books. Currently he a member of the WHO collaborating group for OMPDs and cancer, and is a lead author for ICCR guidelines. Philip is particularly enthusiastic about working with industry partners as well as academic researchers, for patient benefit.

Sarah Cockman
QUALITY ASSURANCE & REGULATORY AFFAIRS MANAGER

Sarah Cockman has over 10 years’ experience in quality and regulatory management gained in medical devices, specialising in in vitro diagnostics, notably with Leica Biosystems and Biosignatures Ltd.

As AMLo moves towards commercialisation of its lead biomarker, AMBLor, for prognosis of early stage melanoma, Sarah will bring a robust approach to ensuring our QMS and regulatory strategies provide excellent standards of compliance to ensure patients and clinicians can rely on AMLo products.

Sarah Cockman
QUALITY ASSURANCE & REGULATORY AFFAIRS MANAGER

Sarah Cockman has over 10 years’ experience in quality and regulatory management gained in medical devices, specialising in in vitro diagnostics, notably with Leica Biosystems and Biosignatures Ltd.

As AMLo moves towards commercialisation of its lead biomarker, AMBLor, for prognosis of early stage melanoma, Sarah will bring a robust approach to ensuring our QMS and regulatory strategies provide excellent standards of compliance to ensure patients and clinicians can rely on AMLo products.

Dr David Swan
IVD PRODUCT DEVELOPMENT MANAGER

David has a strong academic research background. He completed his PhD in Immunology at Newcastle University in 2011, and then carried out post-doctoral work at the University until 2019. This included leading part of a clinical study to find cellular biomarkers that would predict flare in rheumatoid arthritis patients.

More recently, David has held successive Development Scientist roles in small local biotech companies. He gained experience in product development across the development timeline: from the scientific concept stage through to the validation stage, carrying out experiments that had been stress-tested with key external stakeholders. David joins AMLo as IVD Product Development Manager and will take responsibility for development of our four IVD product lines.

Dr David Swan
IVD PRODUCT DEVELOPMENT MANAGER

David has a strong academic research background. He completed his PhD in Immunology at Newcastle University in 2011, and then carried out post-doctoral work at the University until 2019. This included leading part of a clinical study to find cellular biomarkers that would predict flare in rheumatoid arthritis patients.

More recently, David has held successive Development Scientist roles in small local biotech companies. He gained experience in product development across the development timeline: from the scientific concept stage through to the validation stage, carrying out experiments that had been stress-tested with key external stakeholders. David joins AMLo as IVD Product Development Manager and will take responsibility for development of our four IVD product lines.

AMLo Biosciences Limited is a company registered in England and Wales. Company # 11004534

Trading address: Office 9, The Biosphere, Drayman's Way, Newcastle Helix, Newcastle upon Tyne, NE4 5BX

Registered address: c/o RMT Accountants & Business Advisors Ltd, Gosforth Park Avenue, Newcastle upon Tyne, NE12 8EG, United Kingdom

VAT # 285288950

Sign up for our newsletter